Department of Obstetrics and Gynecology, Keio University School of Medicine, 35, Shinanomachi Shinjyukuku, Tokyo, 160-8582, Japan.
Department of Pathology, Keio University School of Medicine, Tokyo, Japan.
Stem Cell Res Ther. 2020 Jul 20;11(1):300. doi: 10.1186/s13287-020-01809-1.
Despite recent advances in neonatal care, sepsis remains a leading cause of mortality in neonates. Mesenchymal stem cells derived from various tissues, such as bone marrow, umbilical cord, and adipose tissue, have beneficial effects on adult sepsis. Although human amniotic fluid stem cells (hAFSCs) have mesenchymal stem cell properties, the efficacy of hAFSCs on neonatal sepsis is yet to be elucidated. This study aimed to investigate the therapeutic potential of hAFSCs on neonatal sepsis using a rat model of lipopolysaccharide (LPS)-induced sepsis.
hAFSCs were isolated as CD117-positive cells from human amniotic fluid. Three-day-old rat pups were intraperitoneally treated with LPS to mimic neonatal sepsis. hAFSCs were administered either 3 h before or at 0, 3, or 24 h after LPS exposure. Serum inflammatory cytokine levels, gene expression profiles from spleens, and multiple organ damage were analyzed. hAFSC localization was determined in vivo. In vitro LPS stimulation tests were performed using neonatal rat peritoneal macrophages co-cultured with hAFSCs in a cell-cell contact-dependent/independent manner. Immunoregulation in the spleen was determined using a DNA microarray analysis.
Prophylactic therapy with hAFSCs improved survival in the LPS-treated rats while the hAFSCs transplantation after LPS exposure did not elicit a therapeutic response. Therefore, hAFSC pretreatment was used for all subsequent studies. Inflammatory cytokine levels were elevated after LPS injection, which was attenuated by hAFSC pretreatment. Subsequently, inflammation-induced damages in the brain, lungs, and liver were ameliorated. hAFSCs aggregated with peritoneal macrophages and/or transiently accumulated in the liver, mesentery, and peritoneum. Paracrine factors released by hAFSCs induced M1-M2 macrophage polarization in a cell-cell contact-independent manner. Direct contact between hAFSCs and peritoneal macrophages further enhanced the polarization. Microarray analysis of the spleen showed that hAFSC pretreatment reduced the expression of genes involved in apoptosis and inflammation and subsequently suppressed toll-like receptor 4 signaling pathways.
Prophylactic therapy with hAFSCs improved survival in a rat model of LPS-induced neonatal sepsis. These effects might be mediated by a phenotypic switch from M1 to M2 in peritoneal macrophages, triggered by hAFSCs in a cell-cell contact-dependent/independent manner and the subsequent immunomodulation of the spleen.
尽管新生儿医学最近取得了进展,但败血症仍然是新生儿死亡的主要原因。来源于骨髓、脐带和脂肪组织等多种组织的间充质干细胞对成人败血症有有益的影响。虽然人羊水干细胞(hAFSCs)具有间充质干细胞特性,但 hAFSCs 对新生儿败血症的疗效尚未阐明。本研究旨在使用脂多糖(LPS)诱导的败血症大鼠模型来研究 hAFSCs 对新生儿败血症的治疗潜力。
从人羊水分离出 CD117 阳性细胞作为 hAFSCs。3 日龄大鼠腹腔内注射 LPS 以模拟新生儿败血症。hAFSCs 在 LPS 暴露前 3 小时或暴露后 0、3 或 24 小时给予。分析血清炎症细胞因子水平、脾基因表达谱和多器官损伤。在体内确定 hAFSC 定位。采用 LPS 刺激新生大鼠腹腔巨噬细胞与 hAFSCs 共培养的细胞-细胞接触依赖/非依赖方式进行体外 LPS 刺激试验。采用 DNA 微阵列分析确定脾免疫调节。
hAFSCs 预防性治疗可提高 LPS 处理大鼠的存活率,而 LPS 暴露后 hAFSCs 移植则无治疗反应。因此,所有后续研究均采用 hAFSC 预处理。LPS 注射后炎症细胞因子水平升高,hAFSC 预处理可减轻其升高。随后,大脑、肺和肝脏的炎症损伤得到改善。hAFSCs 与腹腔巨噬细胞聚集并/或短暂积聚在肝脏、肠系膜和腹膜。hAFSCs 分泌的旁分泌因子以细胞-细胞接触非依赖的方式诱导 M1-M2 巨噬细胞极化。hAFSCs 与腹腔巨噬细胞的直接接触进一步增强了极化。脾的微阵列分析显示,hAFSC 预处理可降低凋亡和炎症相关基因的表达,并随后抑制 Toll 样受体 4 信号通路。
hAFSCs 预防性治疗可提高 LPS 诱导的新生败血症大鼠的存活率。这些作用可能是通过 hAFSCs 以细胞-细胞接触依赖/非依赖的方式诱导腹腔巨噬细胞从 M1 向 M2 的表型转换,并随后对脾脏进行免疫调节来介导的。